Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BHVNBullishCorporate Developmentsnews

High materiality9/10

Biohaven inks global Kv7 license with SK, secures up to $795M and royalties

Aug 26, 2026, 2:39 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Non-dilutive cash improves BHVN's balance sheet; milestone upside and royalties provide optionality; a potential near-term catalyst from RISE3 results; leverages SK's commercial capabilities to de-risk Opakalim's path.

AI summary

What happened, with direct paths to the underlying reporting

Biohaven and SK Biopharmaceuticals announced a global licensing deal granting SK an exclusive worldwide license to Biohaven's Kv7 platform led by opakalim. The agreement delivers up to $795 million in upfront and milestone payments and tiered US royalties, providing non-dilutive capital while preserving long-term upside. RISE3 topline results due in 2H 2026 could serve as a near-term catalyst.

Biohaven and SK strike global Kv7 license; upfront/milestones up to $795M.
Royalties on US net sales expected in mid-teens to low-20s.
Opakalim in Phase 2/3; topline results due 2H 2026.
Non-dilutive funding strengthens Biohaven's balance sheet and runway.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.